TrialJournal of clinical hypertension (Greenwich, Conn.)

The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?

Domenic A Sica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.